Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Sep;17(5):470-6.
doi: 10.1097/MNH.0b013e328305b9a5.

Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia

Sirirat Reungjui  1 , Thongchai Pratipanawatr, Richard J Johnson, Takahiko Nakagawa
Affiliations
Review

Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia

Sirirat Reungjui et al. Curr Opin Nephrol Hypertens. 2008 Sep.

Abstract

Purpose of review: The aims of this article are to review the current controversies related to the use of thiazide diuretics as first-line treatment of hypertension and to discuss the causal roles for hyperuricemia and hypokalemia on the adverse consequences of thiazide usage.

Recent findings: Thiazides significantly reduce morbidity and mortality in hypertensive subjects. There remains, however, debate about thiazide usage as first-line treatment of hypertension. This negative impact of thiazides may be partially attributed to the ability of thiazides to exacerbate features of metabolic syndrome or increase the risk for developing diabetes. Several clinical trials suggest that thiazide-induced hyperuricemia and hypokalemia may account for some of these negative effects. Thiazide treatment is also associated with a decline of renal function in spite of a lowering blood pressure. In this review, we discuss the clinical and experimental evidence supporting a potential role of hyperuricemia and hypokalemia on the development of renal injury and worsening of the metabolic syndrome.

Summary: Hyperuricemia and hypokalemia may have pivotal roles in the exacerbation of the metabolic syndrome in response to thiazides. We propose that controlling serum uric acid and serum potassium could improve thiazide efficacy and also reduce its risk for inducing metabolic syndrome or diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed Mechanism for how thiazides exacerbates Metabolic syndrome.
Figure 2
Figure 2
Proposed Mechanism for how thiazides causes renal injury.
See this image and copyright information in PMC

References

    1. Hollander W, Wilkins RW. Chlorothiazide: a new type of drug for the treatment of arterial hypertension. BMQ. 1957;8:69–75. - PubMed
    1. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program(SHEP) JAMA. 1991;265:3255–3264. - PubMed
    1. Patel AB, Kostis JB, Wilson AC, et al. Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program. Stroke. 2008;39:1084–1089. - PubMed
    1. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616–1628. No authors listed. - PubMed
    1. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systemic review and meta-analysis. JAMA. 1997;277:739–745. - PubMed

MeSH terms

Substances